Hypothyroidism
- PMID: 39368843
- DOI: 10.1016/S0140-6736(24)01614-3
Hypothyroidism
Abstract
Hypothyroidism, the deficiency of thyroid hormone, is a common condition worldwide. It affects almost all body systems and has a wide variety of clinical presentations from being asymptomatic to, in rare cases, life threatening. The classic symptoms of hypothyroidism include fatigue, lethargy, weight gain, and cold intolerance; however, these symptoms are non-specific and the diagnosis is typically made on biochemical grounds through serum thyroid function tests. The most common cause of hypothyroidism is chronic autoimmune thyroiditis (Hashimoto's thyroiditis), although other causes, including drugs (such as amiodarone, lithium, and immune checkpoint inhibitors), radioactive-iodine treatment, and thyroid surgery, are frequent. Historically, severe iodine deficiency was the most common cause. Reference ranges for thyroid function tests are based on fixed percentiles of the population distribution, but there is increasing awareness of the need for more individualised reference intervals based on key factors such as age, sex, and special circumstances such as pregnancy. Levothyroxine monotherapy is the standard treatment for hypothyroidism; it is safe and inexpensive, restores thyroid function tests to within the reference range, and improves symptoms in the majority of patients. However, 10% of patients have persistent symptoms of ill health despite normalisation of thyroid function tests biochemically and a substantial proportion of patients on levothyroxine have thyroid-stimulating hormone concentrations outside the reference range. Ongoing symptoms despite levothyroxine treatment has led to some patients using liothyronine or desiccated thyroid extract. Taken together, these factors have led to intense debate around the treatment thresholds and treatment strategies for hypothyroidism. In this Seminar, we review the epidemiology, genetic determinants, causes, and presentation of hypothyroidism; highlight key considerations and controversies in its diagnosis and management; and provide future directions for research.
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests PNT has received funds from the British Thyroid Foundation and the Association of Physicians of GB & Ireland for studies on hypothyroidism, and from PassPACES as an examiner. He received a Leadership and Development Award from the Society for Endocrinology; is Chair of the Welsh Endocrine and Diabetes Society; a member of UK Iodine; and is a member of the British Thyroid Association executive committee. MMM has received financial support from ACE Pharmaceuticals (Zeewolde, the Netherlands) for a randomised controlled trial of levothyroxine–liothyronine replacement in patients with hypothyroidism. AH-D is Principal Investigator and member of the steering committee of the HORIZON 2020 EUThyroid grant; coordinator and Primary Investigator of the GRAN-T-MTC (ERA-NET FP7) grant and the HORIZON 2020 TECANT grant; has received consulting fees and travel support for expert meeting attendance from Institut Biochimique (IBSA) and Recordati; has received speaker honoraria from IBSA, Ipsen, Novartis, Merck, Berlin Chemie—Menarini, and Pfizer; is President of the Polish Society of Endocrinology, Chairperson of the Polish Commission for the Control of Iodine Deficiency Disorders, and Team Leader for the Polish Society of Endocrinology guidelines for the diagnosis and treatment of thyroid diseases; and has participated in an advisory board for Ipsen. KB is President of the British Thyroid Association, Chair of the Clinical Committee and Council Member of the Society for Endocrinology, member of the European Thyroid Association executive committee, and member of the programme organising committee of the American Thyroid Association; she has received grant funding from the National Institute for Health and Care Research (NIHR), Research for Patient Benefit (NIHR200772) and NIHR Health Technology Assessment (NIHR135261); she has received consulting fees from Eli Lilly, Eisai, SERB, Egetis Pharmaceuticals, and the Medicines and Healthcare products Regulatory Agency; she has received speaker honoraria from the Emirates Diabetes and Endocrine Society and Eisai; she has received editor honoraria from Best Practice and Research Clinical Endocrinology and Metabolism, and honoraria from NICE as clinical lead for the Thyroid Diseases guidelines; she was the recipient of the Society for Endocrinology Outstanding Clinical Practitioner Award; she is Associate Editor for the Journal of the Endocrine Society for which she receives honoraria; and is on the international advisory board for The Lancet Diabetes & Endocrinology.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical